Stock DMAC DIAMEDICA THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. DiaMedica Therapeutics Inc.

Equities

DMAC

CA25253X2077

Market Closed - Nasdaq
Other stock markets
 02:00:00 30/04/2024 am IST 		5-day change 1st Jan Change
2.59 USD +0.78% Intraday chart for DiaMedica Therapeutics Inc. +3.19% -8.80%
17/04 DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment MT
17/04 DiaMedica Therapeutics Inc. Announces First Patient Dosed in Relaunch of Its Pivotal Phase /3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Craig Hallum Cuts DiaMedica Therapeutics Price Target to $8 From $11, Maintains Buy Rating
MT
Oppenheimer Trims DiaMedica Therapeutics Price Target to $6 From $7, Maintains Outperform Rating
MT
Oppenheimer Upgrades DiaMedica Therapeutics to Outperform From Perform, $7 Price Target
MT
Oppenheimer Downgrades DiaMedica Therapeutics to Market Perform From Outperform
MT
Lake Street Trims DiaMedica Therapeutics' Price Target to $8 From $14, Keeps Buy Rating
MT
Craig Hallum Lowers DiaMedica Therapeutics' Price Target to $12 From $18, Keeps Buy Rating
MT
Roth Lowers Price Target for DiaMedica Therapeutics to $16 From $24, Maintains Buy Rating
MT
Oppenheimer Adjusts DiaMedica Therapeutics' Price Target to $15 From $17, Maintains Outperform Rating
MT
Maxim Group Adjusts DiaMedica Therapeutics Price Target to $6 From $11, Maintains Buy Rating
MT
Oppenheimer Adjusts DiaMedica Therapeutics PT to $17 From $21, Maintains Outperform Rating
MT
DIAMEDICA THERAPEUTICS : Roth Capital Adjusts DiaMedica Therapeutics PT to $24 From $32, Maintains Buy Rating
MT
DIAMEDICA THERAPEUTICS : Maxim Group Adjusts Price Target on DiaMedica Therapeutics to $11 From $14, Reiterates Buy Rating
MT
DIAMEDICA THERAPEUTICS : Roth Capital Adjusts DiaMedica Therapeutics' Price Target to $32 From $38, Maintains Buy Rating
MT
DIAMEDICA THERAPEUTICS : Oppenheimer Starts DiaMedica Therapeutics at Outperform With $27 Price Target
MT
DIAMEDICA THERAPEUTICS : Craig-Hallum Adjusts Price Target on DiaMedica Therapeutics to $20 From $15, Maintains Buy Rating
MT
DIAMEDICA THERAPEUTICS : Roth Capital Initiates Coverage on DiaMedica Therapeutics at Buy, Sets Price Target at $38
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DMAC Stock
  4. News DiaMedica Therapeutics Inc.
  5. Analyst Reco.